<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745823</url>
  </required_header>
  <id_info>
    <org_study_id>0518-071</org_study_id>
    <secondary_id>2008_543</secondary_id>
    <secondary_id>CTRI/2009/091/000145</secondary_id>
    <nct_id>NCT00745823</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)</brief_title>
  <official_title>A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared
      to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve
      human immunodeficiency virus (HIV)-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may
      enroll in an extension study (MK0518-071-10)(NCT00745823). From weeks 96 to 120, subjects'
      treatment assignments will remain as in the base study.

      From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once daily)
      in combination with TRUVADA™.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg
    once daily versus raltegravir 400 mg twice daily
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;50 Copies/mL at 48 Weeks</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events at 48 Weeks</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;400 Copies/mL at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in CD4 Cell Count</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA &lt;50 Copies/mL at 96 Weeks</measure>
    <time_frame>Week 96</time_frame>
    <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA &lt;400 Copies/mL at 96 Weeks</measure>
    <time_frame>Week 96</time_frame>
    <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 96 in CD4 Cell Count</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Adverse Events at 96 Weeks</measure>
    <time_frame>Week 96</time_frame>
    <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to an Adverse Event at 96 Weeks</measure>
    <time_frame>Week 96</time_frame>
    <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">775</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Raltegravir 400 mg b.i.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir 800 mg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Raltegravir 400 mg b.i.d.</intervention_name>
    <description>Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)</description>
    <arm_group_label>Raltegravir 400 mg b.i.d.</arm_group_label>
    <other_name>ISENTRESS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Raltegravir 800 mg q.d.</intervention_name>
    <description>Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.</description>
    <arm_group_label>Raltegravir 800 mg q.d.</arm_group_label>
    <other_name>ISENTRESS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRUVADA™</intervention_name>
    <description>One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)</description>
    <arm_group_label>Raltegravir 400 mg b.i.d.</arm_group_label>
    <arm_group_label>Raltegravir 800 mg q.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female 18 years of age or older

          -  Patient is HIV positive

          -  Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days
             total of any ART

        Extension Study:

          -  The planned extension study did not take place as the study was terminated after the
             Week 48 analysis.

        Exclusion Criteria:

          -  Patient is a user of recreational or illicit drugs or has had a recent history (within
             the last year) of drug or alcohol abuse or dependence

          -  Patient has documented resistance to tenofovir or emtricitabine

          -  Patient is currently participating or has participated in a study with an
             investigational compound or device within 45 days of signing informed consent

          -  Patient is pregnant or breastfeeding, or expecting to conceive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <results_first_submitted>March 6, 2012</results_first_submitted>
  <results_first_submitted_qc>March 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2012</results_first_posted>
  <disposition_first_submitted>September 29, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2011</disposition_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Treatment Naïve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir 800 mg q.d.</title>
          <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
        <group group_id="P2">
          <title>Raltegravir 400 mg b.i.d.</title>
          <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED Week 0 - 96</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="386"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="349"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir 800 mg q.d.</title>
          <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
        <group group_id="B2">
          <title>Raltegravir 400 mg b.i.d.</title>
          <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="386"/>
            <count group_id="B2" value="389"/>
            <count group_id="B3" value="775"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B3" value="764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;50 Copies/mL at 48 Weeks</title>
        <time_frame>Week 48</time_frame>
        <population>Data were analyzed for all participants treated with study drug. Participants who did not complete the study were treated as treatment failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;50 Copies/mL at 48 Weeks</title>
          <population>Data were analyzed for all participants treated with study drug. Participants who did not complete the study were treated as treatment failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 800 mg q.d. dosage was considered non-inferior to 400 mg b.i.d. if the lower bound of the 2-sided exact 95% CI for difference in response rate remained above -10%.</non_inferiority_desc>
            <p_value>0.044</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;400 Copies/mL at 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
        <population>Data were analyzed for all participants treated with study drug. Participants who did not complete the study were treated as treatment failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV Ribonucleic Acid (RNA) &lt;400 Copies/mL at 48 Weeks</title>
          <population>Data were analyzed for all participants treated with study drug. Participants who did not complete the study were treated as treatment failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 800 mg q.d. dosage was considered non-inferior to 400 mg b.i.d. if the lower bound of the 2-sided exact 95% CI for difference in response rate remained above -10%.</non_inferiority_desc>
            <p_value>0.011</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.29</ci_lower_limit>
            <ci_upper_limit>-1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Adverse Events at 48 Weeks</title>
        <time_frame>Week 48</time_frame>
        <population>Data were analyzed for all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events at 48 Weeks</title>
          <population>Data were analyzed for all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O2" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks</title>
        <time_frame>Week 48</time_frame>
        <population>Data were analyzed for all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks</title>
          <population>Data were analyzed for all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in CD4 Cell Count</title>
        <time_frame>Baseline and Week 48</time_frame>
        <population>Data were analyzed for all participants treated with study drug. Baseline values were carried forward for participants who discontinued treatment due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in CD4 Cell Count</title>
          <population>Data were analyzed for all participants treated with study drug. Baseline values were carried forward for participants who discontinued treatment due to lack of efficacy.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.76" lower_limit="194.6" upper_limit="224.9"/>
                    <measurement group_id="O2" value="196.20" lower_limit="181.8" upper_limit="210.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>13.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.29</ci_lower_limit>
            <ci_upper_limit>34.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA &lt;50 Copies/mL at 96 Weeks</title>
        <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
        <time_frame>Week 96</time_frame>
        <population>The Week 96 data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA &lt;50 Copies/mL at 96 Weeks</title>
          <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
          <population>The Week 96 data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA &lt;400 Copies/mL at 96 Weeks</title>
        <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
        <time_frame>Week 96</time_frame>
        <population>The Week 96 data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA &lt;400 Copies/mL at 96 Weeks</title>
          <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
          <population>The Week 96 data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 96 in CD4 Cell Count</title>
        <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
        <time_frame>Baseline and Week 96</time_frame>
        <population>The Week 96 data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg PO q.d. plus placebo to raltegravir PO b.i.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg b.i.d. administered with TRUVADA™</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 96 in CD4 Cell Count</title>
          <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
          <population>The Week 96 data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Adverse Events at 96 Weeks</title>
        <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
        <time_frame>Week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events at 96 Weeks</title>
          <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to an Adverse Event at 96 Weeks</title>
        <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
        <time_frame>Week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir 800 mg q.d.</title>
            <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir 400 mg b.i.d.</title>
            <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to an Adverse Event at 96 Weeks</title>
          <description>As the study was terminated after the 48-week analysis, the planned secondary analyses for Week 96 were not performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir 800 mg q.d.</title>
          <description>Raltegravir 800 mg by mouth (PO) once daily (q.d.) plus placebo to raltegravir PO twice daily (b.i.d.) plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
        <group group_id="E2">
          <title>Raltegravir 400 mg b.i.d.</title>
          <description>Raltegravir 400 mg PO b.i.d. plus placebo to raltegravir PO q.d. plus one tablet of TRUVADA™ for 96 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Retroperitoneal lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune reconstitution syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Penis injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma AIDS related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="382"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="382"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="81" subjects_affected="70" subjects_at_risk="382"/>
                <counts group_id="E2" events="87" subjects_affected="70" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="382"/>
                <counts group_id="E2" events="57" subjects_affected="54" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="382"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="382"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="382"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="382"/>
                <counts group_id="E2" events="34" subjects_affected="28" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="382"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="382"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="40" subjects_at_risk="382"/>
                <counts group_id="E2" events="70" subjects_affected="54" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="49" subjects_at_risk="382"/>
                <counts group_id="E2" events="70" subjects_affected="54" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="382"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="382"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="382"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="70" subjects_affected="58" subjects_at_risk="382"/>
                <counts group_id="E2" events="87" subjects_affected="62" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="382"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="382"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="40" subjects_affected="38" subjects_at_risk="382"/>
                <counts group_id="E2" events="41" subjects_affected="30" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="382"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="382"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="382"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Twenty-four months after completion of this study or after publication of the multicenter results, an investigator may publish the results for their study site independently. The sponsor must have the opportunity to review all proposed publications or presentations regarding the study 60 days before submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1- 800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

